Will 2009 Be The Year Of M&As For Japanese Drug Makers In Antibody Space?
This article was originally published in PharmAsia News
Executive Summary
The therapeutic market for monoclonal antibodies has grown exponentially since 2000, and Japanese pharmas, like counterparts in the U.S. and Europe, are looking to antibody drug development as a key-growth driver